Filing Flows › AbbVie (ABBV) › Guidance history
AbbVie (ABBV) guidance history: what it guided and what it reported
AbbVie gave guidance in 12 earnings releases on file since Feb 2, 2024. Its releases raised guidance 10 times and lowered it once.
Adjusted EPS
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $14.37–$14.57 (Feb 4, 2026) → lowered $14.08–$14.28 (Apr 29, 2026) → lowered $13.87–$14.07 (Jul 31, 2026) → reaffirmed $13.95–$13.99 (Oct 30, 2026) | — | to be reported | — |
| FY2025 | $12.12–$12.32 (Jan 31, 2025) → lowered $12.09–$12.29 (Apr 25, 2025) → lowered $11.88–$12.08 (Jul 31, 2025) → lowered $10.61–$10.65 (Oct 31, 2025) | — | — | — |
| FY2024 | $11.05–$11.25 (Feb 2, 2024) → raised $11.13–$11.33 (Apr 26, 2024) → lowered $10.71–$10.91 (Jul 25, 2024) → raised $10.90–$10.94 (Oct 30, 2024) | — | — | — |
The latest quarter
AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart follows the revenue to costs, profit and cash.
Questions
Does AbbVie beat its guidance?
AbbVie gave guidance in 12 earnings releases on file since Feb 2, 2024. Its releases raised guidance 10 times and lowered it once.
How often does AbbVie raise guidance?
Its earnings releases raised guidance 10 times and lowered it once since Feb 2, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.